Balance Sheet
Cash Flow Statement
Daily Values
DMA 100DMA 200DMA 50Dividend YieldEV to CFOEV to EBITEV to EBITDAEV to FCFEV to RevenueEnterprise ValueMarket Cap to FCFMarket CapitalizationPricePrice to EarningsPrice to Sales
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Sangamo Therapeutics (SGMO) Enterprise Value (2016 - 2026)

Sangamo Therapeutics (SGMO) has disclosed Enterprise Value for 16 consecutive years, with -$20.9 million as the latest value for Q4 2025.

  • For Q4 2025, Enterprise Value rose 50.14% year-over-year to -$20.9 million; the TTM value through Dec 2025 reached -$20.9 million, up 50.14%, while the annual FY2025 figure was -$20.9 million, 50.14% up from the prior year.
  • Enterprise Value hit -$20.9 million in Q4 2025 for Sangamo Therapeutics, up from -$30.5 million in the prior quarter.
  • Across five years, Enterprise Value topped out at -$20.9 million in Q4 2025 and bottomed at -$588.0 million in Q1 2021.
  • Average Enterprise Value over 5 years is -$182.2 million, with a median of -$89.3 million recorded in 2022.
  • Year-over-year, Enterprise Value plummeted 64.25% in 2021 and then skyrocketed 80.58% in 2024.
  • Sangamo Therapeutics' Enterprise Value stood at -$376.5 million in 2021, then skyrocketed by 73.33% to -$100.4 million in 2022, then soared by 55.0% to -$45.2 million in 2023, then grew by 7.27% to -$41.9 million in 2024, then skyrocketed by 50.14% to -$20.9 million in 2025.
  • According to Business Quant data, Enterprise Value over the past three periods came in at -$20.9 million, -$30.5 million, and -$38.3 million for Q4 2025, Q3 2025, and Q2 2025 respectively.